|
answer text |
<p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed
by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased
demand for Erwinase and because PBL are manufacturing at capacity, until increases
in capacity are brought into beneficial use there will be occasional stock-outs.</p><p>
</p><p>The product is currently in stock in the United Kingdom. The Department has
been informed, it is likely there will be a short stock-out in early February 2019
and then a further batch is planned to be released to Jazz Pharmaceuticals, who are
responsible for the packaging/distribution and allocation of worldwide product supply,
anticipated to reach the UK market by mid-February 2019 which should last until the
end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are
in close contact with, and have been kept informed by the PBL management of short
periods of interrupted supply. PBL have and will be implementing a series of initiatives
to increase capacity and better supply the market in both the short and long term.
PBL are fully aware of the consequences that the unavailability of Erwinase has on
patients and are absolutely committed to working with all involved to resolve any
issues and be able to supply this critical medicine.</p><p> </p><p>The Department
and PHE will continue to monitor the situation closely.</p>
|
|